Trials / Completed
CompletedNCT00829257
Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma
A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- University of Dundee · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish whether addition of extra-fine particle steroid inhalers achieve additional suppression of small airways inflammation when added to 'standard' Fluticasone/Salmeterol combination therapy in refractory asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HFA-BDP | HFA-BDP (Qvar) 100ug 2puff b.i.d |
| DRUG | Fluticasone | Fluticasone propionate Accuhaler 250ug b.i.d. |
| DRUG | Seretide | Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2009-01-27
- Last updated
- 2019-04-12
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00829257. Inclusion in this directory is not an endorsement.